Introduction
Methods
Patient Selection
Data Collection
Predictive Factors
Statistical Analyses
Results
Variables | ICAS-LVO group (n = 74) | Embolic group (n = 157) | p-values |
---|---|---|---|
Age, (years, mean (SD)) | 63.46 ± 9.24 | 65.78 ± 12.44 | 0.140 |
Gender, (male, n (%)) | 57 (77.00%) | 106 (67.50%) | 0.284 |
SBP, (mm Hg, median [IQR]) | 157.53 ± 23.78 | 149.41 ± 23.44 | 0.016 |
DBP, (mm Hg, median [IQR]) | 93.50 [80.00,102.00] | 85.00 [75.00, 95.00] | 0.001 |
Medical history | |||
Hypertension, (n (%)) | 13 (68.42%) | 23 (45.10%) | 0.083 |
Diabetes, (n (%)) | 30 (40.50%) | 35 (22.30%) | 0.009 |
CHD, (n (%)) | 3 (15.79%) | 11 (32.50%) | 0.840 |
AF, (n (%)) | 4 (5.40%) | 83 (52.90%) | < 0.001 |
VHD, (n (%)) | 1 (1.40%) | 18 (11.50%) | 0.090 |
ICAS, (n (%)) | 8 (10.80%) | 6 (3.80%) | 0.075 |
Ischemic stroke, (n (%)) | 15 (20.30%) | 35 (22.30%) | 0.728 |
ICH, (n (%)) | 1 (1.40%) | 5 (3.20%) | 0.708 |
Smoking, (n (%)) | 30 (40.50%) | 42 (26.90%) | 0.037 |
Drinking, (n (%)) | 30 (40.50%) | 42 (26.80%) | 0.035 |
Onset form | |||
Fluctuating symptoms, (n (%)) | 46 (62.20%) | 9 (5.7%) | < 0.001 |
Scores after admission | |||
NIHSS score, (median [IQR]) | 15 [12.00, 20.00] | 19 [16.00, 21.50] | 0.001 |
GCS score, (median [IQR]) | 10 [8.00, 12.00] | 9 [6.00, 11.00] | 0.120 |
MRS score, (median [IQR]) | 4 [4.00, 5.00] | 5 [4.00, 5.00] | 0.423 |
ASPECT (pr-ASPECT), (median [IQR]) | 7.37 [7.00, 8.00] | 7.37 [7.00, 8.00] | 0.305 |
ASITN/SIR score (median [IQR]) | 2.00 [1.00, 3.00] | 1.00 [0.00, 1.00] | < 0.001 |
Occlusive clot signs | |||
Cut-off sign | 18 (24.30%) | 70 (46.40%) | 0.010 |
Claw sign | 11 (14.90%) | 37 (24.70%) | 0.093 |
Meniscus sign | 2 (2.70%) | 15 (8.70%) | 0.163 |
Tram-track sign | 22 (29.70%) | 16 (10.70%) | 0.001 |
Tapered sign | 19 (25.70%) | 14 (14.70%) | 0.010 |
Variables | ICAS-LVO Group (n = 74) | Embolic-LVO Group (n = 157) | p-value |
---|---|---|---|
WBC (109 × /L) median [IQR] | 11.19 [8.29, 13.57] | 9.53 [7.02, 12.51] | 0.035 |
Hb (g/L) median [IQR] | 139.00 [126.75, 148.00] | 132.00 [119.00, 147.68] | 0.106 |
Platelets (109 × /L) mean ± (SD) | 245.67 ± 60.60 | 207.72 ± 64.56 | 0.540 |
HbA1 mean ± (SD) | 6.89 ± 1.74 | 6.34 ± 1.68 | 0.510 |
Neutrophils (×109/L) median [IQR] | 9.80 [6.45, 11.1] | 7.49 [5.56, 11.40] | 0.040 |
Lymphocytes (×109/L) median [IQR] | 1.07 [0.80, 1.58] | 1.26 [0.81, 1.93] | 0.194 |
NLR median [IQR] | 8.47 [5.07, 11.83] | 6.40 [3.80, 10.96] | 0.037 |
VLDL (mmol/L) median [IQR] | 0.71 [0.43, 1.10] | 0.52 [0.31, 0.73] | 0.002 |
LDL (mmol/L) mean ± (SD) | 2.79 ± 1.14 | 2.33 ± 0.85 | 0.010 |
TC (mmol/L) mean ± (SD) | 4.72 ± 1.20 | 4.07 ± 1.08 | 0.090 |
TG (mmol/L) median [IQR] | 1.60 [1.03, 2.41] | 1.12 [0.73, 1.63] | 0.001 |
HDL (mmol/L) median [IQR] | 1.03 [0.90, 1.38] | 1.09 [0.95, 1.31] | 0.896 |
Apo A (nmol/L) median [IQR] | 27.85 [13.20, 68.60] | 25.90 [11.20, 67.37] | 0.379 |
SOD (U/mL) median [IQR] | 138.50 [124.00, 157.00] | 137.00 [120.00, 152.00] | 0.581 |
Fibrinogen (g/L) median [IQR] | 2.60 [2.06, 3.43] | 2.53 [2.08, 3.12] | 0.316 |
INR median [IQR] | 1.01 [0.94, 1.08] | 1.07 [1.01, 1.15] | 0.012 |
APTT(s) median [IQR] | 25.05 [23.00, 29.38] | 26.10 [23.00, 31.50] | 0.451 |
PT median [IQR] | 11.55 [10.90, 12.40] | 12.40 [11.25, 14.20] | < 0.001 |
TT (s) median [IQR] | 18.30 [16.38, 21.23] | 17.60 [16.10, 22.40] | 0.499 |
Procalcitonin median [IQR] | 0.05 [0.05, 0.12] | 0.05 [0.05, 0.11] | 0.337 |
Variable | β‑coefficient | Standard error | Wald | OR (95%CI) | p-value |
---|---|---|---|---|---|
Fluctuating symptoms | 3.071 | 0.599 | 26.245 | 21.56 (6.66, 69.8) | < 0.001 |
NIHSS < 16 | 1.287 | 0.479 | 7.220 | 3.62 (1.42, 9.3) | 0.007 |
AF | −3.312 | 0.717 | 21.321 | 0.04 (0.01, 0.1) | < 0.001 |
ASITN/SIR score | 2.362 | 0.504 | 22.005 | 10.61 (3.96, 28.5) | < 0.001 |
Tapered sign | 1.491 | 0.677 | 4.850 | 4.44 (1.18, 16.8) | 0.028 |
Variables | ICAS-LVO group (n = 19) | Embolic-LVO group (n = 51) | p-value |
---|---|---|---|
Age, (year, mean (SD)) | 62.68 ± 8.62 | 63.24 ± 12.55 | 0.861 |
Male, (n (%)) | 9 (47.37%) | 35 (68.63%) | 0.102 |
SBP, (mm Hg, median [IQR]) | 151.11 ± 23.54 | 146.76 ± 25.72 | 0.523 |
DBP, (mm Hg, median [IQR]) | 93.50 [80.00, 93.00] | 86.58 [80.00, 98.00] | 0.592 |
Medical history | |||
Hypertension, (n (%)) | 13 (68.42%) | 23 (45.10%) | 0.083 |
Diabetes, (n (%)) | 4 (21.05%) | 10 (19.6%) | 0.980 |
CHD, (n (%)) | 3 (15.79%) | 11 (21.57%) | 0.840 |
AF, (n (%)) | 1 (5.26%) | 26 (50.98%) | < 0.001 |
VHD, (n (%)) | 0 (0.00%) | 4 (7.84%) | 0.498 |
ICAS, (n (%)) | 1 (5.26%) | 1 (1.96%) | 0.472 |
Ischemic stroke, (n (%)) | 3 (15.79%) | 6 (11.76%) | 0.963 |
ICH, (n (%)) | 0 (0.00%) | 2 (3.92%) | 0.528 |
Smoking, (n (%)) | 8 (42.10%) | 13 (25.49%) | 0.177 |
Drinking, (n (%)) | 4 (21.05%) | 13 (25.49%) | 0.943 |
Onset form | |||
Fluctuating symptoms, (n (%)) | 46 (62.20%) | 9 (5.7%) | < 0.001 |
Scores after admission | |||
NIHSS score < 16, (n (%)) | 13 (68.42%) | 15 (29.41%) | 0.003 |
GCS score, (median [IQR]) | 10 [8.00, 12.00] | 9 [6.00, 11.00] | 0.120 |
MRS score, (median [IQR]) | 4 [4.00, 5.00] | 5 [4.00, 5.00] | 0.423 |
ASITN/SIR score ≥ 2, (n (%)) | 14 (73.68%) | 13 (25.49) | 0.010 |
Occlusive clot signs | |||
Tapered sign | 16 (25.70%) | 5 (9.80%) | 0.020 |